相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
Tsung-Ying Yang et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2022)
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
Renee Ackley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
Oliver A. Cornely et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Resistance to ceftazidime-avibactam and underlying mechanisms
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae
Justin A. Clark et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Jianguo Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Interplay between β-lactamases and new β-lactamase inhibitors
Karen Bush et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection, Southwest China, 2012-2017
Shuangshuang Yang et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2019)
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program
Daniel J. Diekema et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae
M. Biagi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
Matthew L. Rizk et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline
Joseph Newman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae
Wei Yu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
Eric Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals
Jing Zhang et al.
BMC INFECTIOUS DISEASES (2014)
Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: A comparison of 0.5-h and 3-h infusions
Michal Lips et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Multiplex PCR for detection of acquired carbapenemase genes
Laurent Poirel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion
PK Dandekar et al.
PHARMACOTHERAPY (2003)
分享论文
